lopinavir has been researched along with Chemical and Drug Induced Liver Injury in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (33.33) | 29.6817 |
2010's | 6 (33.33) | 24.3611 |
2020's | 6 (33.33) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Andini, R; Bertolino, L; Corcione, A; Durante-Mangoni, E; Florio, LL; Mele, F; Murino, P; Zampino, R | 1 |
Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
Alberici, I; Cattelan, AM; Di Meco, E; Farinati, F; Fassan, M; Guarnaccia, A; Trevenzoli, M | 1 |
Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
Igari, H; Ishii, I; Nakada, TA; Sayama, M; Suzuki, T; Yamazaki, S | 1 |
Barnes, EL; Kinlaw, AC; Li, X; Moon, AM; Tang, H; Wang, T; Yang, JY; Zhou, L | 1 |
Barrail-Tran, A; Borand, L; Connolly, C; Duc, NH; Dung, NH; Harries, AD; Lagarde, D; Lan, NN; Lan, NT; Laureillard, D; Lien, TT; Lienhardt, C; Pym, A; Quillet, C; Taburet, AM; Thu, NT | 1 |
Aldeguer, JL; Tasias, M | 1 |
Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
Curran, A; Ribera Pascuet, E | 1 |
Antela López, A | 1 |
Bini, T; Bonfanti, P; Cristina, G; Miccolis, S; Orofino, G; Penco, G; Quirino, T; Ricci, E; Sfara, C | 1 |
Carter, M | 1 |
Manfredi, R; Sabbatani, S | 1 |
Battegay, M; Blick, G; Kraft, M; Neubacher, D; Opravil, M; Raffi, F; Rusconi, S; Sabo, JP; Steigbigel, RT | 1 |
2 review(s) available for lopinavir and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
[Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Topics: AIDS Dementia Complex; Chemical and Drug Induced Liver Injury; Drug Combinations; Hepatitis, Viral, Human; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lopinavir; Renal Insufficiency; Reverse Transcriptase Inhibitors; Ritonavir; Subarachnoid Space | 2014 |
[Safety and tolerability of darunavir].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lopinavir; Male; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
3 trial(s) available for lopinavir and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Asian People; Biological Availability; Chemical and Drug Induced Liver Injury; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis; Vietnam | 2014 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
13 other study(ies) available for lopinavir and Chemical and Drug Induced Liver Injury
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Convalescence; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Humans; Hydroxychloroquine; Lopinavir; Multiple Organ Failure; Pandemics; Pneumonia, Viral; Ritonavir; RNA, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2 and hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Chemical and Drug Induced Liver Injury; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Diagnosis, Differential; Drug Combinations; Hepatitis, Viral, Human; Humans; Liver; Liver Function Tests; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
Topics: Aged; Amides; Antiviral Agents; Chemical and Drug Induced Liver Injury; Cholestasis; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Humans; Lopinavir; Male; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; COVID-19; Drug Combinations; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir; United States; United States Food and Drug Administration | 2021 |
Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Italy; Liver Diseases; Lopinavir; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrimidinones; Ritonavir | 2005 |
Focus on hepatitis. Low rate of liver problems seen with LPV/r.
Topics: Chemical and Drug Induced Liver Injury; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Liver; Lopinavir; Pyrimidinones; Ritonavir | 2005 |
Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function.
Topics: Adult; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Myelopoiesis; Pyrimidinones | 2006 |
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Topics: Alanine Transaminase; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Lopinavir; Peptide Fragments; Pyridines; Pyrimidinones; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome; Viral Load | 2007 |